Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Jixian Wang, Sanhita Sengupta, Ram Tiwari
{"title":"Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis.","authors":"Jixian Wang, Sanhita Sengupta, Ram Tiwari","doi":"10.1080/10543406.2025.2519153","DOIUrl":null,"url":null,"abstract":"<p><p>The use of real-world data, containing data from historical clinical studies, to construct an external control arm or to augment a small internal control arm in a randomized control trial can lead to significant improvements in the efficiency of the trial, but it may also introduce bias. To mitigate the risk of potential bias arising from the heterogeneity between the external control and the internal control arms, Bayesian dynamic borrowing, which determines the amount of borrowing by similarity between the two data sources, using power prior approaches and covariate adjustment has been introduced. For binary and continuous outcomes, an approach integrating propensity score for covariate adjustment and Bayesian dynamic borrowing using power prior has been proposed. Here, we extend this approach to survival analysis with the hazard ratio as the estimand. We propose a novel approach for estimating the amount of borrowing using the empirical Bayes method based on the log-hazard ratio between external and internal controls. For inference, the approach uses Bayesian bootstrap in combination with the empirical Bayes method, covariate adjustment, and multiple imputation, taking into account all uncertainty. The performance of our approach is examined by a simulation study. As an illustration, we apply the approach to dynamic borrowing of Flatiron real-world data for CheckMate-057 study for advanced non-squamous non-small cell lung cancer. For this application, we apply multiple imputation for missing covariates and propose a computationally efficient algorithm for computing the total variance of the log hazard ratio estimate. The proposed method can be applied to other endpoints in oncology as well as to other disease areas.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-22"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2519153","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The use of real-world data, containing data from historical clinical studies, to construct an external control arm or to augment a small internal control arm in a randomized control trial can lead to significant improvements in the efficiency of the trial, but it may also introduce bias. To mitigate the risk of potential bias arising from the heterogeneity between the external control and the internal control arms, Bayesian dynamic borrowing, which determines the amount of borrowing by similarity between the two data sources, using power prior approaches and covariate adjustment has been introduced. For binary and continuous outcomes, an approach integrating propensity score for covariate adjustment and Bayesian dynamic borrowing using power prior has been proposed. Here, we extend this approach to survival analysis with the hazard ratio as the estimand. We propose a novel approach for estimating the amount of borrowing using the empirical Bayes method based on the log-hazard ratio between external and internal controls. For inference, the approach uses Bayesian bootstrap in combination with the empirical Bayes method, covariate adjustment, and multiple imputation, taking into account all uncertainty. The performance of our approach is examined by a simulation study. As an illustration, we apply the approach to dynamic borrowing of Flatiron real-world data for CheckMate-057 study for advanced non-squamous non-small cell lung cancer. For this application, we apply multiple imputation for missing covariates and propose a computationally efficient algorithm for computing the total variance of the log hazard ratio estimate. The proposed method can be applied to other endpoints in oncology as well as to other disease areas.

贝叶斯动态功率先验借用,用于增强控制臂的生存分析。
使用真实世界的数据,包括历史临床研究的数据,在随机对照试验中构建外部对照组或增加小型内部对照组,可以显著提高试验的效率,但也可能引入偏倚。为了减轻外部控制和内部控制臂之间的异质性所带来的潜在偏差风险,引入了贝叶斯动态借用,该借用使用幂先验方法和协变量调整,通过两个数据源之间的相似性来确定借用的数量。对于二元和连续结果,提出了一种利用幂先验综合倾向得分进行协变量调整和贝叶斯动态借用的方法。在这里,我们将这种方法扩展到以风险比作为估计的生存分析。我们提出了一种基于外部和内部控制之间的对数风险比的经验贝叶斯方法来估计借款金额的新方法。对于推理,该方法采用贝叶斯自举法结合经验贝叶斯方法,协变量调整和多重插值,考虑了所有不确定性。通过仿真研究验证了该方法的性能。作为一个例子,我们将该方法应用于动态借用Flatiron真实世界数据,用于晚期非鳞状非小细胞肺癌的CheckMate-057研究。对于这个应用,我们对缺失的协变量应用多重插值,并提出了一个计算效率高的算法来计算对数风险比估计的总方差。所提出的方法可以应用于肿瘤学的其他终点以及其他疾病领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信